11/03/2025
A new oral treatment improved clinical remission and endoscopic outcomes for patients with moderately to severely active ulcerative colitis who had failed multiple prior therapies, results from two phase III trials showed.
The results, while encouraging, warrant further research, Alan Moss, MD, the Foundation's Chief Scientific Officer, told MedPage Today.
"Obefazimod represents a potential therapy with a new mechanism of action for patients with moderate-severe ulcerative colitis who have failed other treatments," said Moss, who was not involved in the studies. "This short-term study confirms its ability to induce clinical remission and improve colonic inflammation in these patients. However, further studies will be crucial to confirm these benefits over a longer period and in more diverse patient groups." Read more: https://bit.ly/4olysnM